| 000 | 01374 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250518004514.0 | ||
| 264 | 0 | _c20191016 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a2051-1426 | ||
| 024 | 7 |
_a10.1186/s40425-018-0430-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGambichler, Thilo | |
| 245 | 0 | 0 |
_aParaneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy. _h[electronic resource] |
| 260 |
_bJournal for immunotherapy of cancer _c10 2018 |
||
| 300 |
_a113 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aFatal Outcome |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIpilimumab _xadverse effects |
| 650 | 0 | 4 |
_aLeukocytosis _xchemically induced |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 |
_aNivolumab _xadverse effects |
| 650 | 0 | 4 |
_aParaneoplastic Syndromes _xchemically induced |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 700 | 1 | _aStockfleth, E | |
| 700 | 1 | _aSusok, L | |
| 773 | 0 |
_tJournal for immunotherapy of cancer _gvol. 6 _gno. 1 _gp. 113 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s40425-018-0430-y _zAvailable from publisher's website |
| 999 |
_c28993661 _d28993661 |
||